Who We Are
Lucence is a precision oncology company founded on a vision of a world without avoidable cancer deaths. The Company develops advanced liquid biopsy blood tests that select suitable cancer treatments by molecular profiling. Headquartered in Singapore and California, with offices in Hong Kong and Suzhou, Lucence supplies molecular diagnostic services for innovative cancer testing worldwide through a US CLIA-licensed, CAP and ISO15189-accredited laboratory.
A world without avoidable cancer deaths.
To achieve early cancer detection, better treatment and less suffering through deep genome intelligence.
We see the fight against cancer as a mission. If we can deliver early detection for all cancers to achieve cure, that is something worth our time, our energy, everything.
The story of Lucence began in 1999, when our founder Dr Min-Han Tan (Han) was a medical resident at the university cancer center in Singapore. There he witnessed great suffering, but also saw the ability of modern medicine to alleviate unnecessary pain and distress. This formative experience motivated him to focus his life and career on understanding how to fight and defeat cancer through a deep understanding of the human genome. Han believes that oncology exists where bedside medicine, high technology, deep research and profound spirituality intersect.
Han first completed his medical oncology specialist training. He then went on to pursue his PhD in cancer genetics at the Karolinska Institute, Sweden and National University of Singapore. To seek deeper understanding on genomic medicine, Han joined the Cleveland Clinic in the United States as a research scholar, where he was awarded both the Lee Foundation and Ambrose Monell Cancer Genomic Medicine Fellowships. At the Cleveland Clinic, he and Professor Charis Eng published landmark data models on cancer risk in hereditary breast and thyroid cancers. This work continues to guide the international cancer community in patient care today.
In 2011, Han joined the Agency for Science, Technology and Research (A*STAR) to lead the Laboratory of Systems Medicine and focus on building better genomic technology for cancer patients. Over the next 5 years, Han and his team made key discoveries on the nature of circulating tumor DNA and circulating tumor cells by applying innovative laboratory and machine-learning technologies. His discovery of the circulating tumor-endothelial cluster transformed the liquid biopsy field and overturned decades of scientific dogma. This research led to improved non-invasive screening and profiling of cancer using blood testing.
Han founded Lucence in 2016 to deliver his genomic technology from the laboratory to the world where it was most needed. Lucence’s vision is a world without avoidable cancer deaths through early cancer detection and better treatment selection. The company’s AmpliMARK™ sequencing technology is used in its flagship liquid biopsy test LiquidHALLMARK® to detect cancer-causing mutations and viruses. Its AI platform SunTzu.AI™ centralizes genomic intelligence and maps cancer-fighting strategies for each patient.
In 2017, Lucence raised US$9.2 million in seed funding, one of the largest seed investments raised by a biomedical start-up in Asia Pacific. Today, Lucence’s liquid biopsy tests are available across Asia to help doctors reduce the pain and sufferings of cancer patients.
Achieving a world without avoidable cancer deaths through genomic intelligence is at the core of everything Lucence does.
Raised US$9.2 million seed funding
Lucence sets up first overseas office in Hong Kong
Company expands to 2 cities in San Francisco and Suzhou
Lucence receives CAP and CLIA accreditation
Announcement of US$20 million Series A Funding
We are a venture-backed company with the mission to fight cancer through earlier diagnosis and treatment. We are supported by a group of like-minded investors that understands how great technology is nurtured and developed, the positive impact it can have on lives, and the real difference it can make to humanity.
We partner with healthcare providers and medical laboratories to deliver our cancer diagnostic services to physicians. We also collaborate with hospitals, research institutes and universities to conduct studies that advance the field of genomic medicine.
Our Team Leaders
CEO and Medical Director
Min-Han (Han) is the Founding CEO and Medical Director of Lucence Diagnostics. He is also a visiting consultant at the Division of Medical Oncology, National Cancer Centre Singapore (NCCS), and a visiting scholar at the Faculty of Engineering, Waseda University, Japan. A trained medical oncologist and clinical cancer geneticist, Han obtained his MBBS and PhD from National University of Singapore. He completed his cancer specialist training at NCCS. In 2011, he joined the Agency for Science, Technology and Research (A*STAR) in Singapore to lead the Laboratory of Systems Medicine. Han started Lucence in 2016 to commercialize the liquid biopsy technology his lab developed at A*STAR. Han has published over 100 original research publications and filed 13 patents. He was elected Fellow of the Royal College of Physicians Edinburgh in 2015 and received the A*STAR Outstanding Scientist-Entrepreneur Award in 2018.
Chief Technology Officer
Yukti is the Chief Technology Officer and co-founder of Lucence Diagnostics. A molecular biologist by training, she holds a PhD in Biological Sciences and a BSc (first class honors) in Life Sciences from National University of Singapore. At Lucence, Yukti is responsible for creating new molecular diagnostic technology for cancer detection and treatment. She leads a team of scientists and data professionals to harness the genomic information of patients for better clinical decision-making. Prior to Lucence, she was a research scientist at the Agency for Science, Technology and Research (A*STAR). Yukti has made breakthrough discoveries of new treatment targets for brain and kidney cancers. Notably, she developed the first patient-specific, stem cell-based method for modeling drug-induced liver toxicity. Yukti has been recognized for her scientific contributions by the American Society of Clinical Oncology and was named a “Promising Young Investigator” by the Kidney Cancer Association in 2016.
Chief Financial Officer
With over 10 years of experience in accounting, assurance, and taxation, Kevin oversees the financial operations of the company. His assurance background with KPMG has given him a keen understanding of company growth, compliance needs, and project management. In his previous role as the Financial Controller of a listed healthcare company, he developed his skills in operations and workflow management. He is a chartered accountant and holds a Bachelor’s degree in Accountancy from Nanyang Technological University. Kevin is also a seven-time national chess champion, a globally recognized chess writer, and Singapore’s next Chess Grandmaster.
Wai Min Phyo
Wai Min drives assay development and quality assurance at Lucence. Trained in medicine and engineering, he has a track record of successful technology licensing to industry. Prior to Lucence, Wai Min worked at Dr. Min-Han Tan’s lab at the Agency for Science, Technology and Research (A*STAR), where he developed novel PCR-based diagnostics that have been commercialized for real-world clinical usage. He was also instrumental in setting up a tissue bank for research and development in colorectal cancer, a collaboration between A*STAR and Fortis Colorectal Hospital. He holds an MBBS from University of Medicine (I), Yangon and a Master’s degree in Engineering from National University of Singapore.
Jess oversees operational matters and manages key projects at Lucence. She is adept at navigating business growth and operations with her profound understanding of team dynamics. Prior to joining Lucence, she worked in Dr. Min-Han Tan’s lab at the Agency for Science, Technology and Research (A*STAR). There, she led and published several key research studies in cancer diagnostics and liquid biopsies. She co-invented a liquid biopsy test that detects early-stage nasopharyngeal cancer which has been commercialised at Lucence. Jess has also been key in the successful filing of new patents at Lucence with her experience in intellectual property management. She graduated with a BSc (Hons) in Biological Sciences from Nanyang Technological University.
Jack is responsible for organizing the diverse data streams that empower cancer patients and healthcare providers to make the best treatment decisions possible. Based in San Francisco, he also helps Lucence maximize research and commercial opportunities in the United States. An entrepreneur at heart, Jack previously co-founded CliniCast – a startup that helped providers in the US and Singapore organize complex cancer information for research and patient treatment. After Elekta acquired CliniCast in 2015, he helped grow Elekta’s operational analytics portfolio to a global customer base. Jack holds a PhD in Physics from Yale University.
Regional Director and Product Management Head
Hilary is the regional director for Hong Kong, Macau and Taiwan. She is also responsible for product management at Lucence. With her deep expertise in both the commercial and technical aspects of biotechnology, she focuses on delivering our flagship liquid biopsy test to physicians and patients. Hilary comes with extensive international experience growing medical diagnostics across Asia, Europe, Africa, Middle East and Latin America. She holds a BSc in Biological Sciences from The University of Hong Kong and a MSc in Marketing from City University of Hong Kong.
Hao currently oversees the growth and architecture of our AI-driven data analytics platform SunTzu.AI™, which spans genetics and image-based approaches to precision medicine. He has an accomplished track record of creating highly innovative software platforms for analyzing biological and cellular diversity at the Agency for Science, Technology and Research (A*STAR). Regularly ranked among the top downloads on Bioconductor, the primary open-source biological software repository in the world, his algorithms provide insights on high-dimensional and high-throughput single-cell complex data analysis. Hao’s work has been published in top peer-reviewed journals, and he has filed patents on technology for automated and reproducible analysis of complex data. He received his BSc in Biotechnology from Harbin Institute of Technology (China) and MSc in Bioinformatics from Nanyang Technological University (Singapore).
Investments and Legal
Investments and Legal
Gabriel has extensive experience managing international commercial transactions. He spearheads investor relations and provides legal advice towards Lucence’s scalability and growth in its core markets. He is a former corporate counsel and brings with him experience from a listed property investment company and the Singapore Land Authority. He is called to the Singapore Bar and holds an LLB from the University of Nottingham.
Sales & Marketing
Sales & Marketing
Hilda is responsible for expanding our business operations to new markets in Asia. Hilda has extensive frontline experience in the healthcare and biomedical sectors, which enables her to build strong working relationships with new and existing customers. She holds a BSc in Biomedical Sciences from the University of Bradford.
Service Lead (NGS)
Daniel joined Lucence to pursue his interest in the clinical applications of next-generation sequencing (NGS) for clinical research and now leads our team performing NGS assays for our flagship LiquidHALLMARK® test. He is also involved in the development and validation of NGS assays to bring the technology from bench to bedside. Daniel graduated with a PhD from the University of Malaya.
Market Lead (China)
Aster leads market development for Lucence in Mainland China. She has more than 5 years of sales and marketing experience in diagnostics and cancer screening across South East Asia and Hong Kong. Aster holds a MSc from Hong Kong Baptist University.
People & Organizational Development
People & Organizational Development
Yvonne focuses on people development and organizational effectiveness at Lucence. She holds a Bachelor of Arts from Kyoto University and is proficient in Japanese. Yvonne enjoys learning foreign languages and being a part of multicultural environments.
Yong Herng Low
Yong Herng oversees laboratory management at Lucence. He played a key role in achieving Lucence’s early milestones of clinical laboratory licensing from the Singapore’s Ministry of Health and ISO 15189 accreditation. Yong Herng joined Lucence from the Singapore General Hospital, where he was a key operator of the External Quality Assurance Program and Safety Program for its biochemistry laboratory. With his background as an underwater combat medic for Singapore’s elite Naval Diving Unit, Yong Herng is skilled in working with highly focused teams to solve complex operational problems. He graduated with a BSc (first class honors) in Medical Bioscience from Aston University.
Join Our Team
Lucence is a precision oncology company with offices in Singapore, California, Hong Kong and Suzhou.
We have assembled a dynamic team of physicians, scientists, geneticists, bioinformaticians and data analysts who are passionate about the work we do here to improve cancer care. We come from different backgrounds and nationalities but are focused on a single mission – to fight cancer and save lives.
Join our team to transform the way we fight cancer.
Click here to view our open positions.